RAAHA

In 2021 and 2022, Dr. Srinivasan participated in a meeting of trade associations and the U.S. FDA to discuss the hardships experienced by innovators, generic drug manufacturers, and over-the-counter drug manufacturers in detection, control, and risk mitigation related to nitrosamine impurities and the use of molecular weight corrections in justifying acceptable intakes of nitrosamine impurities... RAAHA walks hand in hand with clients through the drug development process, helping with the approval and life cycle management of generics and new drugs.

Also known as: Raaha LLC